iPSC-Derived Islet Organ-Chip Models for Human T2D Phenotypes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current rodent models for studying type 2 diabetes (T2D) are poorly predictive of human disease mechanisms and drug efficacy due to the inability to replicate the wide range of insulin secretion and sensitivity defects in humans, leading to high drug development costs.
Innovation Solution
Development of human Organ-chip models using induced pluripotent stem cells (iPSCs) to generate pancreatic progenitor cells through specific culturing protocols, including the use of Activin A, CHIR99021, FGF10, Noggin, and retinoic acid, followed by differentiation into endocrine cells capable of insulin production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If rodent models are used to study type 2 diabetes, then research can be conducted with available models, but the predictive accuracy for human disease mechanisms and drug efficacy is poor
Solution Approach 1:
The patent creates human organ-chip models that copy and replicate human pancreatic tissue architecture and function in vitro, rather than using rodent models. This allows direct study of human disease mechanisms and drug responses, significantly improving predictive accuracy while maintaining the ability to study various T2D phenotypes through differentiated human stem cells
Solution Approach 2:
The patent changes the fundamental parameter of model organism from rodent to human cells, and changes the culture condition parameter from standard 2D culture to 3D organ-chip architecture with physiological flow conditions. This enables the model to recapitulate human-specific disease mechanisms and phenotypes that rodent models cannot predict
2Manufacturing precision
If complex differentiation protocols are used to generate pancreatic progenitor cells, then cell specificity is improved, but the number of differentiation steps increases
Solution Approach 1:
The patent uses pre-formulated differentiation media containing optimized combinations of growth factors and small molecules that are prepared in advance. This allows complex differentiation protocols to be executed as simplified sequential media changes rather than requiring complex simultaneous manipulations, reducing operational complexity while maintaining high differentiation specificity
Solution Approach 2:
The patent employs small molecule inhibitors and growth factors as intermediaries to mediate and control the differentiation process. These chemical mediators precisely regulate signaling pathways to guide stem cell differentiation through specific stages, achieving high cell specificity through chemical control rather than complex mechanical or procedural steps
Data Source
Figure 1
Figure 2
Figure 3A~3C
AI summary
Type 2 diabetes (T2D) is a clinical syndrome caused by insufficient insulin secretion for insulin requirements. described herein are compositions and methods for microphysiological MPS models of disease (MODs) for diabetes. These platforms allow one to compare the effect of chronic β-cell stimulation in the presence and absence of patient specific immune cells in IPSC-derived islets from each group. Additionally, one can reproduce the T2D β-cell phenotype, using islets-on-chips will also be exposed to gluco-lipotoxicity. Likewise, skeletal muscle-on-chips are exposed to patient specific activated immune cells, variable motor neuron innervation and lipids characteristic of T2D.